4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 78 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,927,205 | -2.0% | 308,500 | +39.2% | 1.28% | +33.4% |
| Q2 2023 | $4,006,119 | -25.8% | 221,700 | -29.4% | 0.96% | -40.8% |
| Q1 2023 | $5,397,660 | -26.4% | 314,000 | -4.8% | 1.62% | -36.6% |
| Q4 2022 | $7,329,300 | +159.9% | 330,000 | -5.9% | 2.55% | +118.8% |
| Q3 2022 | $2,820,000 | +24.3% | 350,700 | +7.9% | 1.16% | +13.9% |
| Q2 2022 | $2,269,000 | -53.8% | 325,000 | 0.0% | 1.02% | -33.0% |
| Q1 2022 | $4,914,000 | -2.2% | 325,000 | +41.9% | 1.53% | +43.2% |
| Q4 2021 | $5,024,000 | – | 229,000 | – | 1.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 377,777 | $15,659,000 | 5.43% |
| BVF INC/IL | 1,106,070 | $45,847,000 | 1.80% |
| Eagle Health Investments LP | 50,000 | $2,073,000 | 1.33% |
| Ally Bridge Group (NY) LLC | 150,000 | $6,218,000 | 1.07% |
| Casdin Capital, LLC | 780,555 | $32,354,000 | 0.96% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $163,227,000 | 0.45% |
| Pinz Capital Management, LP | 19,900 | $825,000 | 0.38% |
| ArrowMark Colorado Holdings LLC | 1,063,744 | $44,092,000 | 0.34% |
| Perceptive Advisors | 600,256 | $24,881,000 | 0.27% |
| ACUTA CAPITAL PARTNERS, LLC | 20,000 | $829,000 | 0.23% |